Clinical expression, epidemiology, and monitoring of Mycoplasma gallisepticum and Mycoplasma synoviae: an update

Publication date

2022-02

Authors

Feberwee, Anneke
de Wit, SjaakORCID 0000-0002-3459-1000ISNI 0000000365748522
Dijkman, Remco

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

taverne

Abstract

Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) are of clinical and economic importance for the global poultry industry. Many countries and integrations are involved in monitoring programmes to control both mycoplasma species. This review provides an extensive historic overview of the last seven decades on the development of the knowledge regarding the factors that influence the clinical expression of the disease, the epidemiology, and monitoring of both MG and MS. This includes the detection of new virulent strains, studies unravelling the transmission routes, survival characteristics, and the role of other avian hosts. Also the role of molecular typing tests in unravelling epidemiology and factors that complicate the interpretation of test results is discussed. The latter includes the presence of heterologous mycoplasma infections, the use of heterologous oil-emulsion vaccines, and the use of antibiotic treatments. Also the occurrence of MG and MS strains with low virulence and the use of live and/or inactivated MS and MS vaccines are discussed.

Keywords

Mycoplasma gallisepticum, Mycoplasma synoviae, expression, epidemiology, monitoring, review, Taverne, SDG 3 - Good Health and Well-being

Citation

Feberwee, A, de Wit, S & Dijkman, R 2022, 'Clinical expression, epidemiology, and monitoring of Mycoplasma gallisepticum and Mycoplasma synoviae : an update', Avian Pathology, vol. 51, no. 1, pp. 2-18. https://doi.org/10.1080/03079457.2021.1944605